X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-breast-cancer-drug-combination-fails-late-stage-trial-2024-06-18/
https://www.ema.europa.eu/en/documents/overview/truqap-epar-medicine-overview_en.pdf
https://endpts.com/chmp-recommends-eight-new-drug-approvals-six-label-expansions/
https://www.contractpharma.com/contents/view_breaking-news/2023-11-20/astex-earns-astrazeneca-milestone-for-truqap-approval/?widget=listSection
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-astrazenecas-breast-cancer-drug-combination-2023-11-16/
https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer.html
https://www.biopharmadive.com/news/astrazeneca-breast-cancer-serd-atk-trial-results/634975/
https://www.fiercebiotech.com/biotech/treading-where-roche-and-sanofi-failed-astrazeneca-racks-breast-cancer-wins-akt-and-serd
https://www.icr.ac.uk/news-archive/breast-cancer-drug-capivasertib-enters-major-trial
https://www.forbes.com/sites/elaineschattner/2018/11/14/a-spark-of-good-news-for-precision-oncology-in-breast-cancer/#6accc24b46ff
Market Place
Share 
